Abstract
Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Current Pharmaceutical Design
Title:How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease
Volume: 23 Issue: 31
Author(s): Salvatore Santo Signorelli*
Affiliation:
- Department of Clinical and Experimental Medicine, University of Catania; General Medicine Division, University Hospital “G.Rodolico. Catania,Italy
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Abstract: Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Export Options
About this article
Cite this article as:
Signorelli Santo Salvatore*, How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612823666170608083605
DOI https://dx.doi.org/10.2174/1381612823666170608083605 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Relevance of Long-Term Adherence to Non-Pharmacological and Pharmacological Treatment of Hypertension
Current Hypertension Reviews Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Current Gene Therapy Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics
Current Drug Therapy The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pharmacologic Treatment for Prehypertension: To Treat or Not to Treat?
Recent Patents on Cardiovascular Drug Discovery Preface
Current Cardiology Reviews Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Approaches to the Management of Acute Kidney Injury in Children
Recent Patents on Biomarkers Possible Non-Classic Intracellular and Molecular Mechanisms of LDL Cholesterol Action Contributing to the Development and Progression of Atherosclerosis
Current Vascular Pharmacology Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index to Volume 1
Current Pharmacogenomics Meet Our Editorial Board Member
Current Drug Safety Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology
Current Vascular Pharmacology